55 results
In this study we aim to evaluate the effectivity of the current, standard treatment of uncomplicated urinary tract infections with fosfomycin, based on urine concentrations of fosfomycin in urine in healthy volunteers after receiving a single, oral…
Step 1 Primary objective: To describe the population pharmacokinetics of flucloxacillin for non-critically ill patients and determine the influence of covariates (demographics and renal function) on the kinetics of flucloxacillin. Step 2Primary…
Development and prospective validation of a pharmacokinetic model of flucloxacillin for dosing in patients with impaired renal function.
The purpose of the study is to investigate how quickly and to what extent RO7033877 and CMS are getting into your blood stream and how long your body takes to get rid of it (this is called pharmacokinetics) when they are given alone or given at the…
To identify and clone antibodies that can neutralize the bacterial pathogens Escherichia coli and Pseudomonas aeruginosa.
The purpose of this study is to provide insight in to what extent clinically significant systemic absorption of tobramycin occurs (resulting in a serum tobramycin concentration> 1.0 mg / L) in ICU and Medium Care ICU patients who are being…
The aim of this study is to describe the utility of beta-lactam and fluoroquinolone TDM programs in tertiary ICUs. Therefore, the main objective is to document whether empirical antibiotic dosing regimens of these antibiotics achieve defined…
To investigate whether the current dosing regimen of ciprofloxacin, recommended by the Dutch *Stichting Werkgroep Antibioticabeleid* (SWAB) and applied at the Academic Medical Center for patients with various degrees of renal function admitted at…
Primairy objectivesTo study the pharmacokinetics (plasma and cerebrospinal fluid) of meropenem in infants <= 90 days of postnatal age with probable or confirmed bacterial meningitis (BM); To describe the safety profile of meropenem in the…
To assess piperacillin concentrations during continuous dosing of P/T in critically ill patients; to determine PK variables, e.g. creatinine clearance, leading to a predictive mathematical model enabling TDM and ideally establishing better a priori…
The first objective to investigate is the pharmacokinetics of DP tobramycin using the Cyclops® at four different dosages. The other objective is the local tolerability of DP tobramycin using the Cyclops® at four different dosages.
To determine the number of therapeutic first trough levels (vancomycin serum concentrations between 10 and 15 mg/L), when receiving a starting dose of 90 mg/kg/day. Furthermore, the number of subtherapeutic (serum concentration < 10 mg/L) and…
The purpose of the study is to investigate how quickly and to what extent GSK2251052 is absorbed, distributed, metabolized (converted) and eliminated from the body (this is called pharmacokinetics). The compound to be administered will be labeled…
The objective of the proposed pilot study is to explore acceptability and feasibility of structured and adequate symptomatic treatment in adult women with uncomplicated UTI.
To investigate the Ertapenem plasmaconcentration time curves in a dosingscheme of three administrations per week after hemodialysis in patients with end stage renal disease depending on hemodialysis. To find a pharmacokinetic model to describe…
Study the clearance of immunoglobulin free light chains by HDF, lf-HD and high flux hemodialysis (hf-HD) using polysulphone and polyamide dialyzers.
Objective: To study the frequency of measurable gentamicin serum levels in patients with gentamicin PMMA-beads in situ.
This study aims to assess the efficacy and potency of newly developed small molecule inhibitors of the GC-C signaling pathway and of the CFTR chloride channel in native human intestinal tissue.
To investigate the clinical pharmacokinetics of tobramycin and/or colistin after nasal administration. With this pharmacokinetic parameters the safety of this treatment can be investigated.
The primary objective of this study is to provide an updated pharmacokinetic profile of orally administered nitrofurantoin in women aged 55 to 75 years.